These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8251913)

  • 41. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
    Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
    Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
    Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymerase chain reaction: a method for monitoring tumor cell purge by long-term culture in BCR/ABL positive acute lymphoblastic leukemia.
    Fabrega S; Laporte JP; Giarratana MC; Douay L; Fouillard L; Da WM; Perrot C; Barbu V; Gorin NC
    Bone Marrow Transplant; 1993 Feb; 11(2):169-73. PubMed ID: 8435666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction.
    Cross NC; Feng L; Bungey J; Goldman JM
    Leuk Lymphoma; 1993; 11 Suppl 1():39-43. PubMed ID: 8251914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
    Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
    Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [DNA diagnosis of human cancers: lymphoid malignancies and leukemia].
    Takaku F
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):37-43. PubMed ID: 1987900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
    Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
    J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different tools for the diagnosis and molecular follow-up of leukemias and lymphomas.
    Sayagués JM; Sarasquete ME
    Med Clin (Barc); 2018 Mar; 150(5):202-203. PubMed ID: 29162275
    [No Abstract]   [Full Text] [Related]  

  • 50. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results.
    Campana D
    Int J Clin Lab Res; 1994; 24(3):132-8. PubMed ID: 7819592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular diagnosis of lymphoma.
    Veronese ML; Schichman SA; Croce CM
    Curr Opin Oncol; 1996 Sep; 8(5):346-52. PubMed ID: 8914800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluorescence in situ hybridization in leukemia. Applications in diagnosis, subclassification, and monitoring the response to therapy.
    Anastasi J
    Ann N Y Acad Sci; 1993 Mar; 677():214-24. PubMed ID: 8494210
    [No Abstract]   [Full Text] [Related]  

  • 53. Molecular diagnosis of leukemias using activated oncogenes.
    Ishikawa F; Hirai H
    Jpn J Med; 1990; 29(6):661-2. PubMed ID: 2101421
    [No Abstract]   [Full Text] [Related]  

  • 54. Minimal residual disease in leukaemia and lymphoma.
    Cotter FE; Price C; Young BD; Lister TA
    Ann Oncol; 1990; 1(3):167-70. PubMed ID: 2261362
    [No Abstract]   [Full Text] [Related]  

  • 55. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance.
    Campana D; Pui CH
    Blood; 1995 Mar; 85(6):1416-34. PubMed ID: 7888664
    [No Abstract]   [Full Text] [Related]  

  • 56. Minimal residual disease in hematologic disorders.
    Faderl S; Kurzrock R; Estrov Z
    Arch Pathol Lab Med; 1999 Nov; 123(11):1030-4. PubMed ID: 10539902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Malignant lymphoma. Diagnostic approaches. 4. Chromosome and gene examinations].
    Nomura K
    Nihon Naika Gakkai Zasshi; 2008 Jul; 97(7):1561-77. PubMed ID: 18720597
    [No Abstract]   [Full Text] [Related]  

  • 58. CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias.
    Vedula RS; Karp HQ; Koob J; Lim F; Garcia JS; Winer ES; Luskin MR; Ghiaur G; Kim AS; Beppu LW; Sala-Torra O; Radich J; Gootenberg J; Abudayyeh O; Zhang F; Lindsley RC
    Blood; 2024 Sep; 144(12):1290-1299. PubMed ID: 38976877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer diagnosis by molecular genetic probes: the present and the promise.
    Fey MF; Tobler A
    Ann Oncol; 1991 Oct; 2(9):629-33. PubMed ID: 1742219
    [No Abstract]   [Full Text] [Related]  

  • 60. Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy.
    Bartram CR
    Clin Chim Acta; 1993 Jul; 217(1):75-83. PubMed ID: 8222285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.